Despite the subtle change and lack of immediate impact on patients, the FDA Modernization Act 2.0 is anything but inconsequential, as Pepper Bio's Samantha Dale explains
Be part of the only industry focused event exclusively addressing discovery, translational and reverse translational challenges for Cytokine-Based drug developers.
The success of the dermatology industry in 2022, with approvals for Alopecia Areata and Vitiligo, brings new opportunity for dermatology drug development.
North America's Definitive Microbiome Drug Development Event Dedicated to Moving the Needle Forward on Microbial-Based Drug Development Innovation and Healthcare Industry Adoption.
